Associated Papers
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S8
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma.
Chi AS et al.
Jco Precision Oncology, 2020
Mutated ephrin receptor genes in non-small cell lung carcinoma and their occurrence with driver mutations-targeted resequencing study on formalin-fixed, paraffin-embedded tumor material of 81 patients.
Mäki-Nevala S et al.
Genes, Chromosomes & Cancer, 2013
Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K et al.
Genes, Chromosomes & Cancer, 2013
Select a paper to view details